Home Ingredients Lithium Orotate
Mood & Mental HealthCognitive

Lithium Orotate

Evidence Level
Preliminary
2 Clinical Trials
5 Documented Benefits
1/5 Evidence Score

Lithium orotate is a low-dose form of lithium (the mood-stabilizing element) bound to orotate. CRITICAL DISTINCTION: this is NOT pharmaceutical lithium carbonate (used for bipolar at 600-1,800 mg/day with serum monitoring). Lithium orotate provides typically 5-20 mg of ELEMENTAL lithium per dose — far below pharmaceutical doses. Used in integrative medicine for mood support, cognitive function, and emerging research on neuroprotection. Limited RCT evidence; mechanism interest is significant.

Studied Dose 5-20 mg elemental lithium/day (lithium orotate 130-520 mg providing ~4.6%-20% lithium); CRITICAL: pharmaceutical lithium carbonate doses (600-1,800 mg with serum monitoring) are 30-100× higher and entirely different clinical context
Active Compound Lithium (elemental) bound to orotic acid

Benefits

Mood Support (Subclinical / Integrative)

Sartori 1986 (a small open-label trial) and integrative clinical experience suggest low-dose lithium orotate may support mood stability. EVIDENCE BASE EXTREMELY LIMITED — primarily anecdotal and small uncontrolled studies. Not equivalent to pharmaceutical lithium for bipolar disorder.

Supported by Trial 1, Trial 2

Neuroprotection (Theoretical)

Lithium has well-established neuroprotective mechanisms — increases BDNF, inhibits GSK-3β, promotes neurogenesis. Pharmaceutical doses show neuroprotection in bipolar patients. Whether low-dose lithium orotate provides meaningful neuroprotective benefit is unclear; epidemiologic data on environmental lithium intake is suggestive but not causative.

Supported by Trial 2, Trial 1

Cognitive Function (Theoretical)

Pharmaceutical lithium has cognitive effects; lithium orotate's effects at supplemental doses unclear. Some integrative practitioners use for ADHD, anxiety, mild cognitive decline; evidence base limited.

Supported by Trial 2

Population Studies — Suicide and Drinking Water Lithium

Multiple ecological studies show INVERSE correlation between drinking water lithium content and suicide rates / homicide rates / dementia incidence. Suggests low environmental lithium exposure may have public health benefits — HOWEVER ecological evidence cannot establish causation; supplementation evidence to translate this is essentially absent.

Supported by Trial 2

Alzheimer's Disease Research

trial of low-dose lithium (300 mg lithium carbonate, much higher than orotate doses) in mild cognitive impairment showed modest cognitive preservation. Generated continuing research interest. Lithium orotate at much lower doses unstudied for this indication.

Supported by Trial 2

Mechanism of action

1

GSK-3β Inhibition

Lithium inhibits glycogen synthase kinase-3β (GSK-3β) — multiple downstream effects including: reduced tau hyperphosphorylation (Alzheimer's relevant), increased Wnt signaling, neurogenesis support. Mechanism well-established but requires lithium concentrations achievable mainly with pharmaceutical doses.

2

BDNF Increase

Lithium increases brain-derived neurotrophic factor (BDNF) — supports neuroplasticity and neurogenesis. Therapeutic mechanism in bipolar disorder.

3

Inositol Depletion

Lithium reduces inositol levels in CNS — affects intracellular signaling. Mechanism for mood stabilization in bipolar disorder.

4

Lithium Orotate Specific Pharmacology

Hypothesis that orotate carrier improves lithium bioavailability or tissue distribution vs other lithium forms. EVIDENCE IS WEAK — original 1970s claims by Hans Nieper not robustly replicated. Supplemental dosing (5-20 mg elemental Li) achieves serum lithium far below pharmaceutical reference range (0.4-1.2 mEq/L).

Clinical trials

1
Lithium Orotate for Alcoholism

Open-label trial of lithium orotate (150 mg/day, providing ~5 mg elemental lithium) in 42 alcoholics for up to 6 years.

42 alcoholics (open-label).

Reported reductions in alcohol consumption and improved mood. EXTREMELY LIMITED METHODOLOGY — open-label, no controls. Often cited as 'evidence' for lithium orotate but methodologically weak.

2
Pharmaceutical Lithium for MCI

Clinical trial of lithium carbonate (300 mg/day) vs placebo in 45 patients with mild cognitive impairment for 1 year.

45 MCI patients.

Lithium associated with reduced tau hyperphosphorylation in CSF and trends toward cognitive preservation. PHARMACEUTICAL LITHIUM doses, much higher than orotate; conclusions don't directly translate to lithium orotate supplementation.

Side effects and drug interactions

Common Potential side effects

At supplemental doses (5-20 mg elemental Li): generally well-tolerated.
Mild GI distress.
Tremor (rare at supplemental doses; common with pharmaceutical doses).
Polydipsia / polyuria (theoretical at higher doses; common with pharmaceutical doses).
Theoretical thyroid effects (well-established with pharmaceutical doses; minor at supplemental doses).
Theoretical renal effects with very chronic high-dose use.
Acne / skin issues (rare at supplemental doses; common with pharmaceutical doses).
Weight gain (rare at supplemental doses).

Important Drug interactions

ACE INHIBITORS (lisinopril, etc.) — increase lithium levels (clinically significant for pharmaceutical lithium; relevant for any lithium supplementation).
DIURETICS (especially thiazides — hydrochlorothiazide, chlorthalidone) — INCREASE lithium levels; monitor.
NSAIDS (ibuprofen, naproxen, etc.) — increase lithium levels; monitor.
Caffeine — large changes in caffeine intake affect lithium levels.
Methylxanthines, sodium bicarbonate — affect lithium levels.
PSYCHIATRIC MEDICATIONS — those on bipolar/mood medications should consult psychiatrist before lithium orotate.
Pregnancy — pharmaceutical lithium has CARDIAC TERATOGENICITY (Ebstein's anomaly historically; risk smaller than originally thought but real); lithium orotate at supplemental doses theoretical concern; AVOID in pregnancy.
Lactation — lithium passes into breast milk; AVOID during breastfeeding.
Renal impairment — reduce or AVOID; lithium primarily renally excreted.

More Mood & Mental Health Ingredients

Energy
Caffeine
Caffeine, a natural stimulant found in coffee, tea, and other plants, is commonly suppleme…
Men's Health
Folate
Folate, also known as vitamin B9, is a water-soluble vitamin commonly supplemented as foli…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…

Frequently asked questions about Lithium Orotate

What is lithium orotate used for?

Lithium orotate provides a very low dose of lithium (a trace mineral), marketed for mood, calm, and cognitive support. It is distinct from high-dose prescription lithium used for bipolar disorder.

Is lithium orotate the same as prescription lithium?

No. Prescription lithium (carbonate) is used at much higher, carefully monitored doses for bipolar disorder. Lithium orotate supplements provide tiny amounts (often a few milligrams of elemental lithium), marketed for general mood support, with limited research.

How much lithium orotate should I take?

Supplements typically provide about 1 to 5 mg of elemental lithium; follow product labeling. This is far below prescription doses.

Is lithium orotate safe?

At the low supplemental doses it is generally considered low-risk, but human research is limited, and lithium can affect the kidneys and thyroid at higher levels. Those with kidney or thyroid conditions, on medication, or who are pregnant should check with a doctor; do not use it to self-treat a mood disorder.

What is Lithium Orotate?

Lithium orotate is a low-dose form of lithium (the mood-stabilizing element) bound to orotate. CRITICAL DISTINCTION: this is NOT pharmaceutical lithium carbonate (used for bipolar at 600-1,800 mg/day with serum monitoring).